Raludotatug deruxtecan
Raludotatug deruxtecan is a CDH6 ADC in phase 3 for platinum-resistant ovarian cancer.
Phase 1 ORR ~46% in heavily pretreated ovarian cancer; REJOICE-Ovarian01 phase 2/3 versus chemotherapy. Daiichi Sankyo/Merck.
1.Antibody binds CDH6 on the tumour cell surface
- Route
- IV infusion
- Schedule
- 5.6 mg/kg every 3 weeks (phase 2/3 dose)
- Monitoring
- ILD, blood counts
Source: clinicaltrials.gov/study/NCT06161025. Doses are for orientation; the current label governs.
Compare all products across the US, EU, UK, Japan, China and Australia →
- Oct 2024Filing / dealUS
Merck co-development of R-DXd under the Daiichi Sankyo alliance source
| Adverse event |
|---|
| Nausea |
| Fatigue |
| Neutropenia |
| Anaemia |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Investigational (REJOICE-Ovarian01) | not disclosed | — |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Raludotatug deruxtecan" OR ABSTRACT:"Raludotatug deruxtecan" OR TITLE:"R-DXd" OR ABSTRACT:"R-DXd" OR TITLE:"DS-6000" OR ABSTRACT:"DS-6000") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Raludotatug deruxtecan, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductIfinatamab deruxtecan
Shares Tetrapeptide GGFG (maleimide-GGFG-aminomethyl), DXd, Topoisomerase-I inhibitor payloads, Daiichi Sankyo.
- ProductPatritumab deruxtecan
Shares Tetrapeptide GGFG (maleimide-GGFG-aminomethyl), DXd, Topoisomerase-I inhibitor payloads, Daiichi Sankyo.
- ProductPuxitatug samrotecan
Shares Topoisomerase-I inhibitor payloads, Ovarian cancer, Antibody-drug conjugate (ADC).
- TargetClaudin 6
Shares Daiichi Sankyo, Ovarian cancer, Antibody-drug conjugate (ADC).
- PersonNoboru Yamamoto
- PersonToshihiko Doi
- TermT030 (belotecan derivative)
Shares Topoisomerase-I inhibitor payloads, Antibody-drug conjugate (ADC).
- ProductDatopotamab deruxtecan
Shares Tetrapeptide GGFG (maleimide-GGFG-aminomethyl), DXd, Topoisomerase-I inhibitor payloads, Daiichi Sankyo.